| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neonatal Abstinence Syndrome | 41 | 2025 | 63 | 18.640 |
Why?
|
| Opioid-Related Disorders | 55 | 2025 | 354 | 17.920 |
Why?
|
| Analgesics, Opioid | 55 | 2025 | 546 | 11.580 |
Why?
|
| Buprenorphine | 15 | 2025 | 128 | 6.900 |
Why?
|
| Opiate Substitution Treatment | 20 | 2025 | 66 | 6.740 |
Why?
|
| Pregnancy Complications | 22 | 2025 | 567 | 6.500 |
Why?
|
| Medicaid | 16 | 2026 | 268 | 4.020 |
Why?
|
| Infant, Newborn | 65 | 2026 | 8635 | 3.310 |
Why?
|
| Pregnancy | 61 | 2026 | 7512 | 3.260 |
Why?
|
| Health Policy | 9 | 2025 | 234 | 2.620 |
Why?
|
| United States | 62 | 2026 | 12072 | 2.500 |
Why?
|
| Child Welfare | 3 | 2026 | 71 | 2.300 |
Why?
|
| Child Protective Services | 3 | 2026 | 7 | 2.100 |
Why?
|
| Substance-Related Disorders | 7 | 2026 | 496 | 1.990 |
Why?
|
| Female | 96 | 2026 | 70963 | 1.760 |
Why?
|
| Methadone | 8 | 2025 | 135 | 1.590 |
Why?
|
| Health Services Accessibility | 5 | 2026 | 712 | 1.580 |
Why?
|
| Child Health | 4 | 2024 | 72 | 1.570 |
Why?
|
| Tennessee | 15 | 2025 | 51 | 1.570 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2025 | 237 | 1.500 |
Why?
|
| Humans | 118 | 2026 | 131163 | 1.480 |
Why?
|
| Hepatitis C | 5 | 2021 | 381 | 1.340 |
Why?
|
| Child Abuse | 2 | 2026 | 228 | 1.320 |
Why?
|
| Infant, Very Low Birth Weight | 5 | 2025 | 176 | 1.210 |
Why?
|
| Meconium | 2 | 2019 | 13 | 1.160 |
Why?
|
| Premature Birth | 3 | 2025 | 428 | 1.150 |
Why?
|
| Infant | 30 | 2026 | 13352 | 1.120 |
Why?
|
| Umbilical Cord | 2 | 2019 | 56 | 1.120 |
Why?
|
| Insurance, Health | 4 | 2026 | 146 | 1.110 |
Why?
|
| Mothers | 7 | 2023 | 388 | 1.090 |
Why?
|
| Quality Improvement | 5 | 2025 | 722 | 1.050 |
Why?
|
| Practice Patterns, Physicians' | 9 | 2022 | 789 | 1.050 |
Why?
|
| Retrospective Studies | 34 | 2025 | 17753 | 1.000 |
Why?
|
| Electronic Health Records | 2 | 2024 | 844 | 1.000 |
Why?
|
| Infant Mortality | 3 | 2023 | 183 | 0.970 |
Why?
|
| Pregnancy Outcome | 3 | 2025 | 623 | 0.960 |
Why?
|
| Insurance Coverage | 3 | 2026 | 120 | 0.950 |
Why?
|
| Morphine | 1 | 2025 | 81 | 0.860 |
Why?
|
| Maternal-Fetal Exchange | 3 | 2020 | 85 | 0.850 |
Why?
|
| Atrazine | 1 | 2024 | 5 | 0.840 |
Why?
|
| Cross-Sectional Studies | 15 | 2025 | 3829 | 0.840 |
Why?
|
| Adult | 29 | 2026 | 31282 | 0.820 |
Why?
|
| Reproductive Health | 1 | 2024 | 48 | 0.820 |
Why?
|
| Social Stigma | 1 | 2024 | 82 | 0.810 |
Why?
|
| Gender Identity | 1 | 2024 | 76 | 0.810 |
Why?
|
| Politics | 1 | 2024 | 62 | 0.800 |
Why?
|
| Gastroschisis | 1 | 2024 | 58 | 0.790 |
Why?
|
| Drug Overdose | 2 | 2023 | 73 | 0.770 |
Why?
|
| Male | 40 | 2026 | 64957 | 0.760 |
Why?
|
| Meconium Aspiration Syndrome | 1 | 2022 | 13 | 0.760 |
Why?
|
| Cost-Benefit Analysis | 1 | 2025 | 555 | 0.750 |
Why?
|
| Delphi Technique | 1 | 2024 | 283 | 0.750 |
Why?
|
| Young Adult | 20 | 2026 | 10103 | 0.720 |
Why?
|
| Benzodiazepines | 2 | 2020 | 107 | 0.720 |
Why?
|
| Infant, Premature | 4 | 2025 | 872 | 0.720 |
Why?
|
| Consensus | 1 | 2024 | 512 | 0.700 |
Why?
|
| Quality Indicators, Health Care | 1 | 2024 | 240 | 0.700 |
Why?
|
| Hospitals | 3 | 2024 | 435 | 0.690 |
Why?
|
| Parents | 5 | 2025 | 1128 | 0.690 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2021 | 63 | 0.660 |
Why?
|
| Phenobarbital | 2 | 2018 | 32 | 0.650 |
Why?
|
| Mental Health | 3 | 2025 | 378 | 0.650 |
Why?
|
| Financial Management | 1 | 2020 | 13 | 0.650 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2022 | 177 | 0.640 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2021 | 150 | 0.640 |
Why?
|
| Maternal Health | 2 | 2018 | 31 | 0.630 |
Why?
|
| Hospital Costs | 2 | 2020 | 188 | 0.630 |
Why?
|
| Respiratory Insufficiency | 1 | 2022 | 247 | 0.620 |
Why?
|
| Unemployment | 2 | 2019 | 25 | 0.620 |
Why?
|
| Intensive Care Units, Neonatal | 4 | 2021 | 361 | 0.600 |
Why?
|
| Referral and Consultation | 2 | 2023 | 564 | 0.600 |
Why?
|
| Prescription Drugs | 2 | 2017 | 54 | 0.590 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 645 | 0.580 |
Why?
|
| Patient Readmission | 3 | 2021 | 442 | 0.580 |
Why?
|
| Drug Monitoring | 2 | 2026 | 292 | 0.570 |
Why?
|
| Risk Assessment | 4 | 2025 | 3711 | 0.570 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 27 | 0.570 |
Why?
|
| Length of Stay | 8 | 2021 | 1421 | 0.570 |
Why?
|
| Drug Utilization | 1 | 2020 | 164 | 0.570 |
Why?
|
| Hospital Administration | 1 | 2018 | 24 | 0.570 |
Why?
|
| Patient Discharge | 2 | 2020 | 514 | 0.570 |
Why?
|
| Substance Abuse Detection | 1 | 2018 | 40 | 0.560 |
Why?
|
| Maternal Exposure | 2 | 2020 | 150 | 0.550 |
Why?
|
| Incidence | 8 | 2024 | 3360 | 0.540 |
Why?
|
| Appointments and Schedules | 4 | 2022 | 53 | 0.540 |
Why?
|
| Ligation | 1 | 2018 | 134 | 0.540 |
Why?
|
| Hospital Charges | 2 | 2015 | 70 | 0.530 |
Why?
|
| Neonatal Screening | 1 | 2020 | 207 | 0.530 |
Why?
|
| Gastrostomy | 1 | 2018 | 85 | 0.530 |
Why?
|
| Physicians, Primary Care | 1 | 2019 | 100 | 0.530 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2020 | 262 | 0.520 |
Why?
|
| Prescription Drug Misuse | 1 | 2017 | 9 | 0.510 |
Why?
|
| Algorithms | 1 | 2024 | 1680 | 0.510 |
Why?
|
| Hypnotics and Sedatives | 1 | 2018 | 132 | 0.500 |
Why?
|
| Psychotropic Drugs | 1 | 2017 | 123 | 0.480 |
Why?
|
| Cohort Studies | 10 | 2024 | 5063 | 0.480 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2018 | 150 | 0.470 |
Why?
|
| Central Nervous System Stimulants | 1 | 2017 | 133 | 0.470 |
Why?
|
| Taxes | 1 | 2015 | 4 | 0.470 |
Why?
|
| Perinatal Care | 1 | 2016 | 65 | 0.460 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 89 | 0.450 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 339 | 0.450 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 351 | 0.450 |
Why?
|
| State Government | 3 | 2026 | 33 | 0.450 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 682 | 0.450 |
Why?
|
| Tobacco Products | 1 | 2015 | 60 | 0.440 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2015 | 84 | 0.440 |
Why?
|
| Clinical Protocols | 1 | 2016 | 230 | 0.440 |
Why?
|
| Ambulatory Care | 1 | 2018 | 401 | 0.430 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2020 | 514 | 0.420 |
Why?
|
| Pharmaceutical Preparations | 1 | 2015 | 79 | 0.420 |
Why?
|
| Mortality | 1 | 2016 | 264 | 0.420 |
Why?
|
| Phenotype | 1 | 2024 | 4497 | 0.420 |
Why?
|
| Postpartum Period | 5 | 2024 | 245 | 0.410 |
Why?
|
| Child | 20 | 2026 | 26341 | 0.400 |
Why?
|
| Sex Factors | 2 | 2017 | 1356 | 0.400 |
Why?
|
| Narcotic Antagonists | 2 | 2025 | 112 | 0.400 |
Why?
|
| Antipsychotic Agents | 3 | 2024 | 375 | 0.400 |
Why?
|
| Drug Prescriptions | 4 | 2020 | 237 | 0.400 |
Why?
|
| Health Personnel | 1 | 2018 | 541 | 0.400 |
Why?
|
| Rural Population | 3 | 2021 | 276 | 0.360 |
Why?
|
| Child Health Services | 2 | 2026 | 88 | 0.360 |
Why?
|
| Urban Population | 3 | 2019 | 287 | 0.360 |
Why?
|
| Policy Making | 2 | 2025 | 63 | 0.350 |
Why?
|
| Adolescent | 16 | 2026 | 20987 | 0.350 |
Why?
|
| Databases, Factual | 5 | 2021 | 1240 | 0.350 |
Why?
|
| Drug and Narcotic Control | 2 | 2022 | 18 | 0.340 |
Why?
|
| Congenital Abnormalities | 1 | 2015 | 330 | 0.340 |
Why?
|
| Cross Infection | 1 | 2014 | 339 | 0.330 |
Why?
|
| Health Status | 2 | 2025 | 378 | 0.330 |
Why?
|
| Mandatory Reporting | 2 | 2021 | 22 | 0.330 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2014 | 500 | 0.320 |
Why?
|
| Health Surveys | 3 | 2025 | 261 | 0.320 |
Why?
|
| Critical Illness | 1 | 2014 | 630 | 0.310 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2026 | 512 | 0.310 |
Why?
|
| Hepacivirus | 2 | 2021 | 273 | 0.300 |
Why?
|
| Health Expenditures | 2 | 2023 | 136 | 0.300 |
Why?
|
| International Classification of Diseases | 2 | 2021 | 95 | 0.300 |
Why?
|
| Hospitals, Pediatric | 3 | 2021 | 808 | 0.300 |
Why?
|
| Child, Preschool | 11 | 2026 | 15110 | 0.290 |
Why?
|
| Hospitalization | 3 | 2024 | 1950 | 0.290 |
Why?
|
| Prevalence | 4 | 2025 | 2701 | 0.280 |
Why?
|
| Prenatal Care | 2 | 2021 | 345 | 0.280 |
Why?
|
| Forecasting | 2 | 2020 | 351 | 0.270 |
Why?
|
| Health Resources | 2 | 2020 | 131 | 0.240 |
Why?
|
| Logistic Models | 3 | 2025 | 1797 | 0.230 |
Why?
|
| Eligibility Determination | 1 | 2026 | 38 | 0.230 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 3061 | 0.230 |
Why?
|
| Naltrexone | 1 | 2025 | 68 | 0.230 |
Why?
|
| Refuse Disposal | 1 | 2025 | 5 | 0.230 |
Why?
|
| Medical Waste Disposal | 1 | 2025 | 8 | 0.220 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2025 | 129 | 0.220 |
Why?
|
| Smoking | 2 | 2020 | 932 | 0.220 |
Why?
|
| Data Accuracy | 1 | 2024 | 29 | 0.210 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2025 | 71 | 0.210 |
Why?
|
| Herbicides | 1 | 2024 | 11 | 0.210 |
Why?
|
| Infant, Low Birth Weight | 2 | 2025 | 172 | 0.210 |
Why?
|
| Narcotics | 2 | 2021 | 61 | 0.200 |
Why?
|
| Public Opinion | 1 | 2024 | 64 | 0.200 |
Why?
|
| Emergency Service, Hospital | 2 | 2024 | 1224 | 0.200 |
Why?
|
| Transgender Persons | 1 | 2024 | 66 | 0.200 |
Why?
|
| Maternal Age | 2 | 2020 | 136 | 0.200 |
Why?
|
| Public Policy | 1 | 2023 | 55 | 0.190 |
Why?
|
| Anticonvulsants | 1 | 2026 | 363 | 0.190 |
Why?
|
| Language | 2 | 2022 | 219 | 0.190 |
Why?
|
| Depression | 2 | 2025 | 1320 | 0.190 |
Why?
|
| Cannula | 1 | 2022 | 32 | 0.180 |
Why?
|
| Suicidal Ideation | 1 | 2025 | 254 | 0.180 |
Why?
|
| Mental Health Services | 1 | 2025 | 285 | 0.180 |
Why?
|
| Risk Factors | 6 | 2022 | 11074 | 0.170 |
Why?
|
| Fetal Alcohol Spectrum Disorders | 1 | 2021 | 13 | 0.170 |
Why?
|
| Child, Foster | 1 | 2021 | 9 | 0.170 |
Why?
|
| Cesarean Section | 3 | 2021 | 426 | 0.170 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 4066 | 0.170 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1378 | 0.170 |
Why?
|
| Quarantine | 1 | 2021 | 19 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2025 | 919 | 0.170 |
Why?
|
| Schizophrenia | 1 | 2024 | 324 | 0.170 |
Why?
|
| Electronic Prescribing | 1 | 2020 | 31 | 0.160 |
Why?
|
| Public Assistance | 1 | 2020 | 6 | 0.160 |
Why?
|
| Antiemetics | 1 | 2020 | 24 | 0.160 |
Why?
|
| Qualitative Research | 1 | 2024 | 730 | 0.160 |
Why?
|
| Bupropion | 1 | 2020 | 27 | 0.160 |
Why?
|
| Racism | 1 | 2021 | 56 | 0.160 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2020 | 63 | 0.160 |
Why?
|
| Child Care | 1 | 2020 | 15 | 0.160 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2021 | 103 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2021 | 6459 | 0.160 |
Why?
|
| Sex Distribution | 1 | 2020 | 318 | 0.150 |
Why?
|
| Health Services Research | 2 | 2018 | 180 | 0.150 |
Why?
|
| Analgesics | 1 | 2020 | 120 | 0.150 |
Why?
|
| Food Supply | 1 | 2020 | 94 | 0.150 |
Why?
|
| Office Visits | 1 | 2020 | 80 | 0.150 |
Why?
|
| Public Health | 1 | 2021 | 269 | 0.150 |
Why?
|
| Birth Weight | 2 | 2020 | 347 | 0.150 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2020 | 70 | 0.150 |
Why?
|
| Airway Extubation | 1 | 2020 | 70 | 0.150 |
Why?
|
| Models, Statistical | 1 | 2021 | 483 | 0.150 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 5196 | 0.150 |
Why?
|
| Appalachian Region | 1 | 2018 | 1 | 0.140 |
Why?
|
| Primary Prevention | 1 | 2020 | 183 | 0.140 |
Why?
|
| West Virginia | 1 | 2018 | 8 | 0.140 |
Why?
|
| Kentucky | 1 | 2018 | 29 | 0.140 |
Why?
|
| North Carolina | 1 | 2018 | 48 | 0.140 |
Why?
|
| Psychology | 1 | 2019 | 62 | 0.140 |
Why?
|
| Cerebral Intraventricular Hemorrhage | 1 | 2018 | 6 | 0.140 |
Why?
|
| Postnatal Care | 1 | 2018 | 54 | 0.140 |
Why?
|
| Epilepsy | 1 | 2026 | 876 | 0.140 |
Why?
|
| Infant, Premature, Diseases | 1 | 2020 | 255 | 0.140 |
Why?
|
| Death | 1 | 2019 | 78 | 0.130 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2018 | 41 | 0.130 |
Why?
|
| Aftercare | 1 | 2019 | 157 | 0.130 |
Why?
|
| Reproductive Behavior | 1 | 2017 | 8 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2021 | 407 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 275 | 0.130 |
Why?
|
| Vocal Cord Paralysis | 1 | 2018 | 68 | 0.130 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 507 | 0.130 |
Why?
|
| Breast Feeding | 1 | 2019 | 240 | 0.130 |
Why?
|
| Policy | 3 | 2021 | 39 | 0.130 |
Why?
|
| Epidemics | 1 | 2017 | 58 | 0.120 |
Why?
|
| Patient Compliance | 1 | 2020 | 463 | 0.120 |
Why?
|
| Preventive Health Services | 1 | 2017 | 59 | 0.120 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 209 | 0.120 |
Why?
|
| Intention | 1 | 2017 | 105 | 0.120 |
Why?
|
| Cigarette Smoking | 1 | 2017 | 92 | 0.120 |
Why?
|
| Medical Audit | 1 | 2016 | 98 | 0.110 |
Why?
|
| Influenza, Human | 1 | 2022 | 712 | 0.110 |
Why?
|
| Prognosis | 1 | 2025 | 4886 | 0.110 |
Why?
|
| Caregivers | 1 | 2021 | 598 | 0.110 |
Why?
|
| United Kingdom | 1 | 2016 | 267 | 0.110 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 1490 | 0.110 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 143 | 0.110 |
Why?
|
| Canada | 1 | 2016 | 327 | 0.110 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2018 | 259 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1173 | 0.110 |
Why?
|
| Mass Screening | 1 | 2020 | 822 | 0.110 |
Why?
|
| Alcohol Drinking | 1 | 2017 | 341 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2020 | 12936 | 0.100 |
Why?
|
| Middle Aged | 4 | 2026 | 28601 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1295 | 0.100 |
Why?
|
| Chronic Pain | 1 | 2016 | 168 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1882 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1118 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2016 | 1483 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2015 | 396 | 0.090 |
Why?
|
| Comorbidity | 2 | 2014 | 1595 | 0.090 |
Why?
|
| Decision Making | 1 | 2018 | 726 | 0.090 |
Why?
|
| Pain | 1 | 2015 | 450 | 0.090 |
Why?
|
| Pediatrics | 1 | 2022 | 1252 | 0.090 |
Why?
|
| Tonsillectomy | 1 | 2013 | 114 | 0.090 |
Why?
|
| Prescriptions | 2 | 2021 | 46 | 0.080 |
Why?
|
| Anxiety | 1 | 2017 | 1014 | 0.080 |
Why?
|
| Computer Simulation | 2 | 2023 | 674 | 0.080 |
Why?
|
| Inpatients | 1 | 2013 | 562 | 0.070 |
Why?
|
| Registries | 1 | 2015 | 1634 | 0.070 |
Why?
|
| HIV Infections | 1 | 2020 | 2049 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 1410 | 0.060 |
Why?
|
| Delivery, Obstetric | 2 | 2021 | 257 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2025 | 915 | 0.060 |
Why?
|
| Gestational Age | 2 | 2025 | 1224 | 0.060 |
Why?
|
| Pregabalin | 1 | 2026 | 4 | 0.060 |
Why?
|
| Colorado | 1 | 2026 | 22 | 0.060 |
Why?
|
| Virginia | 1 | 2026 | 21 | 0.060 |
Why?
|
| Pharmacoepidemiology | 1 | 2025 | 12 | 0.060 |
Why?
|
| Drug Labeling | 1 | 2025 | 30 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2025 | 158 | 0.050 |
Why?
|
| Chlorpromazine | 1 | 2024 | 12 | 0.050 |
Why?
|
| Florida | 1 | 2023 | 73 | 0.050 |
Why?
|
| Bias | 1 | 2023 | 151 | 0.050 |
Why?
|
| Self Report | 1 | 2025 | 554 | 0.050 |
Why?
|
| Oxycodone | 1 | 2022 | 16 | 0.040 |
Why?
|
| Acute Pain | 1 | 2022 | 20 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2021 | 43 | 0.040 |
Why?
|
| Live Birth | 1 | 2021 | 75 | 0.040 |
Why?
|
| Attitude | 1 | 2022 | 111 | 0.040 |
Why?
|
| Diagnosis-Related Groups | 1 | 2021 | 26 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2013 | 3147 | 0.040 |
Why?
|
| Pediatricians | 1 | 2022 | 78 | 0.040 |
Why?
|
| Pain Clinics | 1 | 2020 | 6 | 0.040 |
Why?
|
| Prescription Drug Monitoring Programs | 1 | 2020 | 8 | 0.040 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2019 | 9 | 0.040 |
Why?
|
| Linear Models | 1 | 2021 | 688 | 0.040 |
Why?
|
| Risk | 1 | 2022 | 726 | 0.040 |
Why?
|
| Criminal Law | 1 | 2019 | 16 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2020 | 761 | 0.030 |
Why?
|
| Administrative Personnel | 1 | 2018 | 27 | 0.030 |
Why?
|
| Aged | 1 | 2016 | 21025 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2018 | 73 | 0.030 |
Why?
|
| Pregnancy, Unplanned | 1 | 2017 | 9 | 0.030 |
Why?
|
| Reproductive Health Services | 1 | 2017 | 24 | 0.030 |
Why?
|
| Patient Safety | 1 | 2022 | 443 | 0.030 |
Why?
|
| Pregnancy Trimester, First | 1 | 2017 | 117 | 0.030 |
Why?
|
| Vaccination | 1 | 2022 | 1060 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2017 | 143 | 0.030 |
Why?
|
| Suicide | 1 | 2019 | 208 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1618 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 398 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2015 | 99 | 0.030 |
Why?
|
| Patient Admission | 1 | 2015 | 185 | 0.030 |
Why?
|
| Health Promotion | 1 | 2017 | 422 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2013 | 151 | 0.020 |
Why?
|
| Postoperative Hemorrhage | 1 | 2013 | 83 | 0.020 |
Why?
|
| Models, Biological | 1 | 2018 | 1371 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 3359 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2013 | 501 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 2825 | 0.020 |
Why?
|